Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524462 | 0.69 | CGAS (0.47) | CGASHCAR2LMNAHSD17B10DAO | |
| SCHEMBL17501768 | 0.69 | — | — | |
| SCHEMBL11969830 | 0.67 | — | — | |
| Water SCHEMBL6788837 | 0.65 | CGAS (0.44) | CGASLMNAALDH1A1HSD17B10 | |
| SCHEMBL231287 | 0.64 | — | — | |
| SCHEMBL5006369 | 0.62 | CGAS (0.42) | CGASLMNA | |
| SCHEMBL12408184 | 0.62 | CGAS (0.42) | CGASLMNA | |
| SCHEMBL10765607 | 0.61 | CGAS (0.41) | CGASLMNAALDH1A1 | |
| SCHEMBL19085970 | 0.61 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL2826925 | 0.60 | KDM4E (0.46) | HCAR2HCAR3LMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018153893-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2018-08-30 | — | — | WO | disclosed |
| US-20180118685-A1 | ANTHRACENE BASED COMPOUNDS AND THEIR USES | UNIVERSITY OF HERTFORDSHIRE HIGHER EDUCATION CORPORATION (GB) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118685-A1 | ANTHRACENE BASED COMPOUNDS AND THEIR USES | CYP2D6, CYP3A43, ACMSD | CGAS 1375/4885HCAR2 404/4885HCAR3 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.